 |
|
Mycosis Fungoides
Disease Evolution and Prognosis of 309 Dutch Patients
Remco van Doorn, MD;
Christian W. Van Haselen, MD;
Pieter C. van Voorst Vader, MD;
Marie-Louise Geerts, MD;
Freerk Heule, MD;
Menno de Rie, MD;
Peter M. Steijlen, MD;
Sybren K. Dekker, MD;
Willem A. van Vloten, MD;
Rein Willemze, MD
Arch Dermatol. 2000;136:504-510.
Objectives To determine the disease course of Dutch patients with mycosis fungoides and to define factors related to disease progression and survival.
Design A multicenter, 13-year, retrospective cohort analysis.
Setting Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma Group.
Patients Three hundred nine patients with mycosis fungoides registered between October 1985 and May 1997, including 89 patients with limited patches or plaques (stage Ia), 135 with generalized patches or plaques (stage Ib), 46 with skin tumors (stage Ic), 18 with enlarged but uninvolved lymph nodes (stage II), 18 with lymph node involvement (stage III), and 3 with visceral involvement (stage IV).
Main Outcome Measures Response to initial treatment, sustained complete remission, actuarial disease progression, and overall and disease-specific survival per clinical stage.
Results The median follow-up was 62 months (range, 1-113 months). For the entire group, the actuarial overall and disease-specific survival was 80% and 89% at 5 years, and 57% and 75% at 10 years, respectively. The actuarial 5-year disease-specific survival of patients with stage Ia, Ib, and Ic disease was 100%, 96%, and 80%, respectively, and only 40% for patients with stage III disease. Using multivariate analysis, the presence of extracutaneous disease, the type and extent of skin involvement, the response to initial treatment, and the presence of follicular mucinosis were independently associated with higher disease progression and mortality rates. The calculated risks of disease progression at 5 and 10 years gradually increased from 4% to 10% for those with stage Ia disease, from 21% to 39% for those with stage Ib disease, and from 32% to 60% for those with stage Ic disease; for those with stage III disease, the risk remained at 70% at 5 and 10 years. The overall risk of disease progression at 5 and 10 years was 24% and 38%, respectively, for the total study group.
Conclusion At least within the first 10 years after diagnosis, disease progression and mycosis fungoides–related mortality occur in only a subset of patients generally presenting with advanced disease.
From the Departments of Dermatology, Free University Hospital (Drs van Doorn and Willemze) and Academic Medical Center (Dr de Rie), Amsterdam, University Medical Center, Utrecht (Drs Van Haselen and van Vloten), University Hospital Groningen, Groningen (Dr van Voorst Vader), University Hospital Rotterdam, Rotterdam (Dr Heule), University of Nijmegen, Nijmegen (Dr Steijlen), and Leiden University Medical Center, Leiden (Drs Dekker and Willemze), the Netherlands; and University Hospital Gent, Gent, Belgium (Dr Geerts). Dr Willemze is now with the Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(4):568-569.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim et al.
Blood 2007;109:4655-4662.
ABSTRACT
| FULL TEXT
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas
Pulini et al.
haematol 2007;92:686-689.
ABSTRACT
| FULL TEXT
Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids: A Prospective Study
de Quatrebarbes et al.
Arch Dermatol 2005;141:1117-1120.
ABSTRACT
| FULL TEXT
WHO-EORTC classification for cutaneous lymphomas
Willemze et al.
Blood 2005;105:3768-3785.
ABSTRACT
| FULL TEXT
Early TCR-{beta} and TCR-{gamma} PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications
Assaf et al.
Blood 2005;105:503-510.
ABSTRACT
| FULL TEXT
Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT
| FULL TEXT
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression
Kim et al.
Arch Dermatol 2003;139:857-866.
ABSTRACT
| FULL TEXT
Phase 1/2 Pilot Study of Methotrexate-Laurocapram Topical Gel for the Treatment of Patients With Early-Stage Mycosis Fungoides
Demierre et al.
Arch Dermatol 2003;139:624-628.
ABSTRACT
| FULL TEXT
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement
Visco et al.
Ann Oncol 2002;13:1290-1299.
ABSTRACT
| FULL TEXT
Follicular Mycosis Fungoides, a Distinct Disease Entity With or Without Associated Follicular Mucinosis: A Clinicopathologic and Follow-up Study of 51 Patients
van Doorn et al.
Arch Dermatol 2002;138:191-198.
ABSTRACT
| FULL TEXT
Lymphoma of the Skin
Connors et al.
ASH Education Book 2002;2002:263-282.
ABSTRACT
| FULL TEXT
CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior
Vermeer et al.
JCO 2001;19:4322-4329.
ABSTRACT
| FULL TEXT
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT
| FULL TEXT
Mycosis Fungoides: What Should Your Patients Expect?
Journal Watch Dermatology 2000;2000:9-9.
FULL TEXT
|
